Royce & Associates LP Purchases 42,474 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Key Points

• Royce & Associates LP increased its stake in Lantheus Holdings by 114.1%, owning approximately 79,699 shares valued at around $7.78 million by the end of the 1st quarter.
• Recent analyst reports have seen a drop in price targets for Lantheus, with B. Riley reducing its target from $122 to $109, although the overall consensus remains a "Moderate Buy" rating.
• Director Mary Anne Heino sold 26,066 shares on June 2nd for over $2 million, indicating a 7.56% decrease in her position in the company.

Royce & Associates LP grew its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 114.1% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 79,699 shares of the medical equipment provider's stock after purchasing an additional 42,474 shares during the quarter. Royce & Associates LP owned about 0.12% of Lantheus worth $7,779,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. lifted its stake in Lantheus by 3.4% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,084 shares of the medical equipment provider's stock valued at $1,162,000 after buying an additional 400 shares during the period. State of Alaska Department of Revenue lifted its stake in Lantheus by 2.7% in the first quarter. State of Alaska Department of Revenue now owns 8,142 shares of the medical equipment provider's stock valued at $794,000 after buying an additional 215 shares during the period. GAMMA Investing LLC increased its holdings in shares of Lantheus by 12,517.1% during the first quarter. GAMMA Investing LLC now owns 128,442 shares of the medical equipment provider's stock valued at $12,536,000 after acquiring an additional 127,424 shares in the last quarter. Pictet Asset Management Holding SA increased its holdings in shares of Lantheus by 12.1% during the fourth quarter. Pictet Asset Management Holding SA now owns 10,294 shares of the medical equipment provider's stock valued at $921,000 after acquiring an additional 1,113 shares in the last quarter. Finally, Cerity Partners LLC increased its holdings in shares of Lantheus by 12.7% during the first quarter. Cerity Partners LLC now owns 11,709 shares of the medical equipment provider's stock valued at $1,143,000 after acquiring an additional 1,323 shares in the last quarter. Institutional investors own 99.06% of the company's stock.

Lantheus Stock Down 0.2%

Lantheus stock traded down $0.15 during trading on Wednesday, hitting $72.05. 65,984 shares of the company were exchanged, compared to its average volume of 1,007,165. The business's 50 day moving average is $77.85 and its 200 day moving average is $88.41. The company has a current ratio of 5.74, a quick ratio of 5.46 and a debt-to-equity ratio of 0.49. Lantheus Holdings, Inc. has a 52 week low of $69.12 and a 52 week high of $118.21. The company has a market capitalization of $4.99 billion, a P/E ratio of 20.46 and a beta of 0.12.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.64 by ($0.11). The business had revenue of $372.76 million during the quarter, compared to the consensus estimate of $377.37 million. Lantheus had a net margin of 16.55% and a return on equity of 36.99%. The firm's revenue for the quarter was up .8% compared to the same quarter last year. During the same quarter last year, the company earned $1.69 EPS. Analysts predict that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. Truist Financial decreased their price objective on Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a report on Thursday, May 8th. Wall Street Zen upgraded Lantheus from a "hold" rating to a "buy" rating in a report on Thursday, May 8th. William Blair reiterated a "market perform" rating on shares of Lantheus in a report on Wednesday, July 16th. Finally, B. Riley decreased their price target on Lantheus from $122.00 to $109.00 and set a "buy" rating for the company in a report on Monday, June 23rd. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat, Lantheus currently has a consensus rating of "Moderate Buy" and a consensus target price of $131.20.

Insider Buying and Selling at Lantheus

In other news, Director Mary Anne Heino sold 26,066 shares of the stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $76.83, for a total transaction of $2,002,650.78. Following the completion of the transaction, the director owned 318,650 shares in the company, valued at approximately $24,481,879.50. This represents a 7.56% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 2.00% of the company's stock.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.